Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015078 | 1.00 | NPC1 (0.68) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL13230076 | 0.94 | NPC1 (0.75) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL30069258 | 0.88 | NPC1 (0.62) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL27457885 | 0.87 | NPC1 (0.60) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL14988733 | 0.87 | RAB9A (0.60) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL18429648 | 0.87 | NPC1 (0.60) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL11121016 | 0.87 | NPC1 (0.60) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL9528862 | 0.87 | HTR1A (0.54) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL31434580 | 0.87 | RAB9A (0.60) | NPC1RAB9ARECQLPOLBTDP1 | |
| SCHEMBL27388637 | 0.86 | HTR1A (0.55) | NPC1RAB9ARECQLPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349442-B1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | UNIV TENNESSEE RES FOUND (US) | 2023-07-26 | — | — | EP | claimed |
| US-11686722-B2 | Compositions and methods to detect molecules in a sample | INFUSENSE CORP. (US) | 2023-06-27 | — | — | US | claimed |
| EP-3629928-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | The University of Tennessee Research Foundation (US) | 2020-04-08 | — | — | EP | claimed |
| US-20190331656-A1 | COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE | INFUSENSE CORP. | 2019-10-31 | — | — | US | claimed |
| EP-3555609-A1 | COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE | Infusense Corp. (US) | 2019-10-23 | — | — | EP | claimed |
| CN-109721586-A | A kind of 5- benzyl -3- pyridyl group -1H-1,2,4- triazole class compounds and its preparation method and application | 中国医科大学 | 2019-05-07 | — | — | CN | claimed |
| WO-2018222820-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-12-06 | — | — | WO | claimed |
| US-20180271413-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | UNITED STATES GOVERNMENT | 2018-09-27 | — | — | US | claimed |
| WO-2018112458-A1 | COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE | INFUSENSE CORP. (US) | 2018-06-21 | — | — | WO | claimed |
| US-9983162-B2 | Method and device for detection of bioavailable drug concentration | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | claimed |
| US-20170370880-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | UNITED STATES GOVERNMENT | 2017-12-28 | — | — | US | claimed |
| US-20150119848-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-04-30 | — | — | US | claimed |
| EP-2856133-A1 | IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION | The University of Tennessee Research Foundation (US) | 2015-04-08 | — | — | EP | claimed |
| WO-2013180814-A1 | IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-12-05 | — | — | WO | claimed |
| US-20120116195-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-05-10 | — | — | US | claimed |
| EP-2349442-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | University of Tennessee Research Foundation (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100121210-A1 | METHOD AND DEVICE FOR DETECTION OFANALYTE IN VAPOR OR GASEOUS SAMPLE | UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2010-05-13 | — | — | US | claimed |
| WO-2010045458-A1 | METHOD AND DEVICE FOR DETECTION OF ANALYTE IN VAPOR OR GASEOUS SAMPLE | UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | claimed |
| WO-2010045465-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | claimed |
| EP-2349442-B1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | UNIV TENNESSEE RES FOUND (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11686722-B2 | Compositions and methods to detect molecules in a sample | INFUSENSE CORP. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11375929-B2 | Method and device for detection of bioavailable drug concentration in a fluid sample | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-07-05 | — | — | US | disclosed |
| CN-108430994-B | Compounds, compositions and methods for modulating CFTR | 蛋白质平衡治疗股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3629928-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | The University of Tennessee Research Foundation (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20190331656-A1 | COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE | INFUSENSE CORP. | 2019-10-31 | — | — | US | disclosed |
| EP-3555609-A1 | COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE | Infusense Corp. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018222820-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-12-06 | — | — | WO | disclosed |
| US-20180271413-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | UNITED STATES GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| WO-2018112458-A1 | COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE | INFUSENSE CORP. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9983162-B2 | Method and device for detection of bioavailable drug concentration | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170370880-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | UNITED STATES GOVERNMENT | 2017-12-28 | — | — | US | disclosed |
| US-9700246-B2 | Method and device for detection of bioavailable drug concentration in a fluid sample | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-07-11 | — | — | US | disclosed |
| CN-104661762-B | Pattern forming method, electronic wiring board, optical element, and pattern forming apparatus | 富士胶片株式会社 | 2016-11-09 | — | — | CN | disclosed |
| CN-104661762-A | Pattern forming method, electronic wiring board, optical element, and pattern forming apparatus | FUJIFILM CORP | 2015-05-27 | — | — | CN | disclosed |
| US-20150119848-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-04-30 | — | — | US | disclosed |
| EP-2856133-A1 | IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION | The University of Tennessee Research Foundation (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-102887880-B | Dibenzofuran derivatives, and preparation method and application thereof | SOUTHEAST UNIVERSITY (CN) | 2014-10-29 | — | — | CN | disclosed |
| WO-2013180814-A1 | IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-12-05 | — | — | WO | disclosed |
| EP-2123627-B1 | PROCESS FOR PRODUCING AROMATIC AMINE HAVING ARALKYLOXY OR HETEROARALKYLOXY GROUP | UBE INDUSTRIES (JP) | 2013-11-20 | — | — | EP | disclosed |
| CN-102887880-A | Dibenzofuran derivatives, and preparation method and application thereof | UNIV SOUTHEAST | 2013-01-23 | — | — | CN | disclosed |
| CN-102736437-A | Pattern formation apparatus and pattern formation method | FUJIFILM CORP | 2012-10-17 | — | — | CN | disclosed |
| US-20120116195-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2349442-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | University of Tennessee Research Foundation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100121210-A1 | METHOD AND DEVICE FOR DETECTION OFANALYTE IN VAPOR OR GASEOUS SAMPLE | UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045458-A1 | METHOD AND DEVICE FOR DETECTION OF ANALYTE IN VAPOR OR GASEOUS SAMPLE | UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045465-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| EP-2123627-A1 | PROCESS FOR PRODUCING AROMATIC AMINE HAVING ARALKYLOXY OR HETEROARALKYLOXY GROUP | Ube Industries, Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1206288-B1 | TARGETED FIBERLESS RADIATIVE EFFECTORS | UNIV MICHIGAN (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1725524-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | disclosed |
| EP-0983288-B1 | SYNTHESIS OF OLIGONUCLEOTIDES | QUIATECH AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| WO-2005092845-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-6933390-B2 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | WARNER-LAMBERT COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-6867201-B2 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER INC (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1189612-A4 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | BARTH HUBERT (DE) | 2004-12-09 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6790946-B2 | GENERATING IMMBOLIZED NUCLEOTIDE SEQUENCES; OBTAIN NUCLEOTIDE SEQUENCES, ATTACH TO SOLID SUPPORT, RELEASE TERMINAL OF OLIGONUCLEOTIDE | QUIATECH AB (SE) | 2004-09-14 | — | — | US | disclosed |
| US-6774242-B1 | REACTING WITH INDOLE IN APROTIC SOLVENT | GOEDECKE GMBH (DE) | 2004-08-10 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1396489-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | Pfizer Products Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1029853-B1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1360007-A1 | METHOD FOR THE PREPARATION OF OPTICAL (BIO)CHEMICAL SENSOR DEVICES | Vir A/S (DK) | 2003-11-12 | — | — | EP | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003012500-A1 | MATERIALS FOR POLYMER OPTICAL FIBERS | RPO PTY LIMITED (AU) | 2003-02-13 | — | — | WO | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| US-6465449-B1 | SUCH AS (6-(4-(6-AMINO-3-AZA-BICYCLO(3.1.0)HEX-3-YLMETHYL)-PHENYL)-QUINAZOLIN-4-YL) -(4-PHENOXY-PHENYL)-AMINE | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| WO-2002066162-A1 | METHOD FOR THE PREPARATION OF OPTICAL (BIO)CHEMICAL SENSOR DEVICES | VIR A/S (DK) | 2002-08-29 | — | — | WO | disclosed |
| US-20020115224-A1 | Method for the preparation of optical (bio)chemical sensor devices | VIR A/S (DK) | 2002-08-22 | — | — | US | disclosed |
| EP-1206288-A2 | TARGETED FIBERLESS RADIATIVE EFFECTORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020051994-A1 | Synthesis of oligonucleotides | KWIATKOWSKI MAREK (SE) | 2002-05-02 | — | — | US | disclosed |
| US-6379955-B1 | Optical fiberless sensors | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-04-30 | — | — | US | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1165512-A2 | METHOD FOR ARYLATING AZA-HETEROCYCLES WITH ACTIVATED AROMATIC COMPOUNDS IN THE PRESENCE OF CESIUM CARBONATE | GÖDECKE GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| US-6313284-B1 | Solid phase synthesis | MAREK KWIATKOWSKI (SE) | 2001-11-06 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2001008660-A2 | TARGETED FIBERLESS RADIATIVE EFFECTORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000059883-A2 | METHOD FOR PRODUCING N-ARYL-AZA-HETEROCYCLES IN THE PRESENCE OF CESIUM CARBONATE | Gödecke GmbH (DE) | 2000-10-12 | — | — | WO | disclosed |
| EP-1029853-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0983288-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | Kwiatkowski, Marek (SE) | 2000-03-08 | — | — | EP | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0469833-B1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY CO ELI (GB) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998051698-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | KWIATKOWSKI MAREK (SE) | 1998-11-19 | — | — | WO | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| US-5622969-A | ADMINISTERING TO HUMAN OR ANIMAL SUFFERING FROM ALLERGIC REACTION OF PULMONARY SYSTEM AND OTHER INFLAMMATORY DISORDERS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5569764-A | USEFUL FOR TREATING ALLERGIC REACTIONS OF PULMONARY SYSTEM, ALLERGIC SKIN DISEASES, RHEUMATIC FEVER, CYSTIC FIBROSIS, AND VASCULAR DISEASES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0335274-B1 | Formation of nitrophenyl ethers from polyols and nitroanisoles | DOW CHEMICAL CO (US) | 1996-03-13 | — | — | EP | disclosed |
| US-5486612-A | FOR TREATING DISEASES WHICH LEUKOTRIENES MEDIATE | ELI LILLY AND COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| EP-0658554-A1 | N-benzyl dihydroindole LTD4 antagonists | ELI LILLY AND COMPANY (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5281593-A | Pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1994-01-25 | — | — | US | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0526093-A1 | New non-steroidal agents as 5-alpha reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5116851-A | Administering antiischemic and antiarrhythmia agents | E. R. SQUIBB & SONS, INC. (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0469833-A1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| EP-0453658-A2 | Use of substituted anilides and sulfonamides in the treatment of cardiovascular diseases | E.R. SQUIBB & SONS, INC. (US) | 1991-10-30 | — | — | EP | disclosed |
| US-4960950-A | Formation of nitrophenyl ethers from polyols and nitroanisoles | THE DOW CHEMICAL COMPANY (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0360566-A2 | Lipoxygenase/cyclooxygenase inhibiting benzoxazolones | PFIZER INC. (US) | 1990-03-28 | — | — | EP | disclosed |
| EP-0335274-A2 | Formation of nitrophenyl ethers from polyols and nitroanisoles | THE DOW CHEMICAL COMPANY (US) | 1989-10-04 | — | — | EP | disclosed |
| EP-0335274-A2 | Formation of nitrophenyl ethers from polyols and nitroanisoles | THE DOW CHEMICAL COMPANY (US) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | NPC1 2939/4885RAB9A 2282/4885RECQL 4883/4885 |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | NPC1 59/4885RAB9A 2271/4885RECQL 4170/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | NPC1 3300/4885RAB9A 1984/4885RECQL 4883/4885 |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | NPC1 757/4885RAB9A 807/4885RECQL 1177/4885 |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | NPC1 284/4885RAB9A 1540/4885RECQL 299/4885 |
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | AZI2, KCNH1, CA7 | NPC1 3071/4885RAB9A 1479/4885RECQL 3995/4885 |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARG, PPARA, PPARD | NPC1 74/4885RAB9A 2063/4885RECQL 4086/4885 |
| US-20020051994-A1 | Synthesis of oligonucleotides | RNGTT, POLR2H, POLR2E | NPC1 4490/4885RAB9A 4781/4885RECQL 1462/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | NPC1 2803/4885RAB9A 847/4885RECQL 2848/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | NPC1 2981/4885RAB9A 2225/4885RECQL 4883/4885 |
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | RCC1, CCNA1, MCL1 | NPC1 390/4885RAB9A 2403/4885RECQL 321/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | NPC1 284/4885RAB9A 1540/4885RECQL 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.